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Abstract
Background: With the development of increasingly sophisticated three-dimensional volumetric imaging methods,
tumor volume can serve as a robust and reproducible measurement of drug efficacy. Since the use of molecularly
targeted agents in the clinic will almost certainly involve combinations with other therapeutic modalities, the use
of volumetric determination can help to identify a dosing schedule of sequential combinations of cytostatic drugs
resulting in long term control of tumor growth with minimal toxicity. The aim of this study is to assess high
resolution sonography imaging for the in vivo monitoring of efficacy of Infliximab in pancreatic tumor.
Methods: In the first experiment, primary orthotopic pancreatic tumor growth was measured with Infliximab
treatment. In the second experiment, orthotopic tumors were resected ten days after inoculation of tumor cells
and tumor recurrence was measured following Infliximab treatment. Tumor progression was evaluated using 3D
high resolution sonography.
Results: Sonography measurement of tumor volume in vivo showed inhibitory effect of Infliximab on primary
tumor growth in both non-resected and resected models. Measurement of the dynamics of tumor growth by
sonography revealed that in the primary tumor Infliximab is effective against established tumors while in the
resection model, Infliximab is more effective at an early stage following tumor resection. Infliximab treatment is
also effective in inhibiting tumor growth growth as a result of tumor cell contamination of the surgical field.
Conclusions: Clinical application of Infliximab is feasible in both the neoadjuvant and adjuvant setting. Infliximab is
also effective in slowing the growth of tumor growth under the peritoneum and may have application in treating
peritoneal carcinomatosis. Finally the study demonstrates that high resolution sonography is a sensitive imaging
modality for the measurement of pancreatic tumor growth.
Background
Pancreatic cancer is the fourth leading cause of cancer
death. It is characterized by high metastasis, uncontrolled
proliferation and resistance to almost all current therapies.
Consequently the prognosis of this disease is poor. Surgery
is the only curative treatment option and is often followed
up with adjuvant systemic chemotherapy and/or radiation.
However, only about 10% of patients can be surgically
treated and for those patients where surgery cannot
remove the entire tumor, chemotherapy with or without
radiation therapy is the best option [1]. The median survi-
val rate following curative resection is less than 21 months
and for non-surgical intervention the five year survival
rate is about 4% [2]. More effective drug therapies and the
ability to assess their effects at the level of the tumor is
crucial for improved patient survival rates.
Animal models play an important role in the develop-
ment and evaluation of new cancer therapies. In particular
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tumors since the blood supply and adjacent tissue more
closely mirror the tumor’s microenvironment. We have
previously described an orthotopic xenotransplant model
in SCID mice for the adjuvant treatment of pancreatic car-
cinoma [3]. In this model a human pancreatic adenocarci-
noma cell line is mixed with matrigel and injected
orthotopically and the tumor is resected 10 days later.
Administration of therapeutic agents can then be used to
determine efficacy in preventing local tumor recurrence
and metastases. Interestingly, very few metastatic lesions
were identified when the tumor was non-resected, sug-
gesting that inflammation associated with resection trig-
gers the growth of metastatic cells [4]. This model has also
been used to include neoadjuvant and extended neoadju-
vant treatment settings prior to tumor resection [5].
For testing of efficacy of cytotoxic chemotherapeutic
agents, endpoint determination of tumor weight of
biopsy samples and histological analyses has been suffi-
cient. This is because the primary mechanism of che-
motherapeutic agents is to perturb the cell cycle during
the cell division or mitotic phase resulting in induction of
apoptosis or necrosis. However, newer therapies which
target signal transduction pathways, such as anti-growth
factor antibodies and small molecule tyrosine kinase inhi-
bitors, may affect important pathways by delaying tumor
progression. In the presence of continued treatment, dif-
ferent responses may be observed at different time points
including zero growth, regression and/or resumption of
growth. Therefore, the monitoring of therapeutic efficacy
and assessing the potential utility of new agents is diffi-
cult with traditional endpoints measurements of tumor
size.
Noninvasive imaging techniques are of considerable
value in the study of drug efficacy since the temporal pat-
tern of the complex dynamics of cancer growth can be
monitored [6]. Ultrasound on the other hand is one of
the major anatomical clinical modalities. Innovative high
frequency sonography permits high resolution imaging of
the micro anatomy and thus is suited to study micro
morphological changes in small animals including tumor
growth in mice. Because high-frequency sound waves
r e q u i r eam e d i u mf o rt r a n s m i s s i o n ,t h e yt r a v e lf a rb e t t e r
through liquids or solids than through air; sonography,
therefore, works well in the abdomen but not in the
thorax. High resolution sonography therefore is a pro-
mising approach for the assessment of pancreatic tumor
growth. Previously high frequency sonography has been
used to detect orthotopic pancreatic tumor growth in a
mouse model and tumor size correlated well with fluor-
escent optical imaging of tumor growth [7]. Detection of
liver metastases also compared favorably with MRI, CT
or optical bioluminescent methods [8-12]. Other mouse
tumor models that have used high frequency ultrasound
for monitoring tumor growth include ovarian, endome-
trial, prostate and bladder cancer [13-16].
We have previously shown that specific inhibition of
TNF-alpha with Infliximab or Etanercept significantly
reduces tumor recurrence, as determined by endpoint
measurement of tumor weight and histological analyses
[4]. The aim of this study is to assess high resolution
sonography for the in vivo monitoring of drug efficacy in
pancreatic tumor. We characterize tumor growth rate
during primary growth and following tumor resection
and demonstrate that sonographic determination of
tumor volume is a sensitive tool for monitoring therapeu-
tic efficacy. The study identifies differences in tumor
growth rate in response to Infliximab and identifes
potential applications of Infliximab in the clinical setting.
Methods
Orthotopic xenograft of human PDAC cells and tumor
resection
Four-week-old female severe combined immunodeficient
beige (SCID/bg) mice weighing 14 to 19 g were obtained
from Harlan-Winkelmann. The mice were allowed to
become acclimatized for 10 days and housed in a sterile
environment, in which bedding, food, and water were
autoclaved (Scantainer). Animal experiments and care
were in accordance with the guidelines of institutional
authorities and approved by the Ethics Committee for
Animal Experiments at Christian-Albrechts-Universität-
zu-Kiel [number, V 362-72241.121 (16-1/06) and V 312-
72241.121-7 (6-1/07)]. Mice were anesthetized with i.p.
injection of 80 mg/kg ketamine (Aveco Co., Inc.) and 10
mg/kg xylazine (Rugby Laboratories, Inc.). A small (f1 cm)
lateral subcostal laparotomy was performed. One million
PancTuII cells, suspended in 20 μL matrigel (BD Bios-
ciences), were injected beneath the capsule of the pancreas
and the abdominal wall and skin were closed.
In the first experiment tumor growth in two groups with
(n = 11) and without Infliximab treatment (n = 9) was
monitored and compared. Infliximab was administered i.p.
(10 μg/g body weight) on days 3, 10, 17, after tumor cell
inoculation.
In the second experiment, tumors were resected ten
days after inoculation of tumor cells. Relaparotomy was
performed and the tumor-bearing pancreas were care-
fully mobilized and resected by subtotal pancreatectomy
as described by us in detail previously. All mice survived
the resection procedure and were randomly assigned to
two groups: Infliximab treatment animals (n = 11), with
application of Infliximab on days 3, 6, 10, 13, 17, 20
after resection. Control mice (n = 11) were injected with
an equivalent volume of 0.9% saline (200 μl) on the
same days. All animals were sacrificed 23 days post-
operatively, and organs and tumors were examined as
described previously.
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During the imaging procedure, mice were anesthetized
with 2% isoflurane vaporized in medical air. Animal tem-
perature was monitored and maintained at 37 C with a
heated imaging platform. Tumor volume assessments
were made by high resolution sonography. Imaging was
performed with a Vevo 770 small animal micro-imaging
system (VisualSonics, Toronto, Ontario, Canada) using a
40 Mhz ultrasound probe with axial resolution of 40 μm
and a 14.6 mm field of view. A transducer with central fre-
quency at 25 MHz, providing axial resolution of 70 μm
with a 20 mm field of view, was used for larger tumor ima-
ging. The pancreatic tumor region of interest was selected
by obtaining cine loops of ultrasound image and an image
frame showing the tumor at it’s largest transverse diameter
was selected for analysis.
Tumor volume was estimated by defining three-
dimensional regions of interest using the VisualSonics
image analysis software package. Two dimensional
images were initially acquired at regular spatial intervals
which were parallel and uniformely spaced at 100 μm.
3D image reconstruction was then performed automated
by the Vevo 770 software (See http://www.visualsonics.
com/vevo770 for additional information). Sonographic
volume measurements were performed at days 7, 12, 17
and 21 in the first experiment and at days 10, 17 and 21
in the second experiment. Figure 1 shows representative
ultrasound image of an orthotopic pancreatic tumor and
peritoneal metastases.
Physical measurements of volume and weight
At necropsy, visible tumors were dissected away from
the normal pancreas and measured ex vivo by placing
them on weighing scale.
Statistical Analyses
All analyses were performed using the JMP software
version 8.0 (SAS Institute, Cary, NC, USA). Multivariate
Analysis of Variance (MANOVA) with repeated mea-
sures were used to identify interaction of group and
temporal response and to study contrasts in temporal
response during specific time periods. T-tests between
groups were performed to compare the growth rates
during various time intervals and also to test for differ-
ences at the final time point to compare the perfor-
mance of the non-invasive imaging methods with the
physical measurements of tumor weight and volume
after sacrificing the animals. Average results per group
are expressed as mean ± standard error of the mean
unless noted otherwise. Figures showing statistical data
were processed using Prism version 5 (GraphPad Soft-
ware, La Jolla, CA, USA).
Results
Comparison of primary pancreatic tumor growth in
response to Infliximab
For the non-resected model, three dimensional sono-
graphic volumetry was performed longitudinally to deter-
mine the effect of Infliximab on orthotopic pancreatic
tumor growth. Analyses were carried out in those 7 con-
trol mice and 11 Infliximab mice (n = 18) that had no
missing data for ultrasound measurements. Primary
tumor volume was found to increase with Infliximab
treatment but overall the increase was at a significantly
slower rate than the untreated group (Figure 2A and
MANOVA repeated measurements F-test p = 0.016).
This is reflected by the overall increase in primary tumor
volume of the Infliximab group from day 7 to day 21,
which amounted to 41% of the increase of the control
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Figure 1 Representative images of pancreatic tumor margins by ultrasound imaging. Difference in echogenity define the tumor from the
surrounding tissue. Tumors are hypoechogen (dark-grayish) compared to surrounding tissue. (A) primary orthotopic pancreatic tumor (red
arrows). The light coloured specks (hyperechogenic) within the tumor may be microcalcifications or fatty deposits. (B) The cross-sectional area of
the primary pancreatic tumor is depicted. The black areas (anechoic) within the tumor are fluid filled cysts correlating to necrotic areas. (C)
Peritoneal tumor with surrounding skin.
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3 vs 416 ± 76 mm
3,p=
0.015). In fact, up to day 17, the tumor volumes between
the two groups were not significantly different but by day
21 a significant difference existed with Infliximab tumor
volume at 43% of the volume in the control group (Figure
2A, 185.2 ± 19.0 mm
3 vs 434.6 ± 79.9 mm
3 p = 0.002).
To obtain insights into the kinetics of action of Inflixi-
mab, growth rate analyses were performed. An assessment
of the growth rate revealed no significant difference from
day 7 to day 12 but from day 12 to day 17 the increase in
the rate of growth of Infliximab tumor was around three
fifth of the untreated tumor (14.0 ± 3.2 mm
3/day vs 24.7 ±
3.8 mm
3/day, p < 0.05). From day 17 to day 21 tumor
growth rate of the treated tumor was around one fifth
(15.1 ± 4.3 mm
3/day vs 69.4 ± 18.0 mm
3/day, p = 0.003).
Therefore Infliximab effect on growth rate is first observed
9 days after administration at a time when the tumor is
established and palpable and it continues thereafter to be
effective. Following sacrifice of the animals, a significant
difference in the weight of the primary tumors was
observed between the two groups (Figure 2B, 266 ± 48 mg
for the Infliximab group versus 427 ± 29 mg for the con-
trol group, p = 0.03). The correlation of sonographically
measured volume and physical measurement of weight
was borderline significant (r2 = 0.2, p = 0.066) and was
strongly influenced by one outlier (after exclusion of this
outlier r2 = 0.31, p = 0.02). Immunohistochemical detec-
tion of pan-cytokeratin was performed on cryosections of
excised pancreatic tumor tissue. Control tumors appeared
to have a greater parenchymal tumor density than Inflixi-
mab treated tumor (See Additional file 1). The cellular
composition of the stroma is currently under investigation.
Comparison of tumor recurrence in response to
Infliximab in the adjuvant treatment setting
In experiment two, those 11 control mice and 9 Inflixi-
mab mice (n = 20) that had no missing data for ultra-
sound measurements were analysed to test whether the
temporal development of the two groups differed. Indeed
we observed a significant difference (Figure 3A and
MANOVA, interaction of group and time p = 0.033).
This is reflected by the overall increase in the Infliximab
g r o u pf r o md a y1 0t od a y2 1w h i c hw a s2 6 %o ft h e
volume increase in the control group (54.2 mm
3 ±2 6 . 5
mm
3 versus 201.6 ± 48.2 mm
3, p = 0.022). In contrast to
primary tumor growth where differences in tumor
volume were observed at the last timepoint, in the
resected model the tumor volume of the treated group
was 26% of the control group already at day 17 (Figure
3A, 48.8 ± 16.7 mm
3 vs 187.7 ± 58.5 mm
3,p=0 . 0 5 2 ) .
The gap widened somewhat more and at day 21 the dif-
ference was statistically significant (72.1 ± 23.4 mm
3 vs
249.5 ± 63.0 mm
3 p = 0.026).
To obtain insights into the kinetics of action of Inflixi-
mab, growth rate analyses was performed. Analyses
revealed a significantly slower tumor growth rate for the
A. B.
Figure 2 Sonographic volume measurement and end-point tumor weight of the primary tumor in the non-resected model. (A)
Sonographic volume measurement and end-point tumor weight of the primary tumor in the non-resected model. Significance of group
differences at each day was determined by 2-tailed student t-test (*: p < 0.002, n = 18). Measurements were performed on the respective day
indicated following tumor cell inoculation. (B) Cross-sectional group differences for volume measurements by sonography (changes between day
7 and 21) or by physical determination of tumor weight (post mortem) n = 20. Box shows 25 - 75 percentile, whiskers 10 - 90 percentiles, +
indicates mean and line the median. Significance was determined by 2-tailed Student t-test (*: p < 0.05, **: p < 0.005).
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mm
3/day vs 19.9 ± 5.1 mm
3/ d a y ,p=0 . 0 2 ) .S u b s e -
quently although there was a difference in the mean
growth rates for both groups between days 17 and 21
this was not statistically significant (5.83 ± 6.2 mm
3/day
vs 15.5 ± 11.3 mm
3/day, p = 0.5).
For the comparison of the ability of weight measure-
ments at the end of the study and noninvasive sono-
graphical assessment of differences in volume at the
end of the study to discriminate between the two treat-
ment groups we could only analyse 16 animals: for 4 of
the 20 animals the local recurrent tumor was not dis-
tinguishable from a secondary tumor growing from
under the skin making weight measurements very inac-
curate. This secondary tumor likely arose from tumor
cell dissemination at the time of surgery. Tumor
weight in the infliximab group was 44.5% of the weight
in the control group (Figure 3B, 264.8 ± 88.3 mg vs
595.1 ± 124.9 mg, p = 0.09). In these 16 animals the
volume difference measure by ultrasound showed a
similar trend (Figure 3B, 71.0 ± 27.1 mm
3 vs 213.1 ±
56.6 mm
3, p = 0.09) while the changes from day 10 to
day 21 remained significant (Figure 3B, 49.7 mm
3 ±
32.1 mm
3 versus 166.9 ± 37.1 mm
3,p<0 . 0 5 ) .T h e
correlation of sonographically measured volume and
physical measurement of weight was highly significant
(r2 = 0.4, p < 0.01).
Comparison of the effect of Infliximab on postoperative
surgical field
To determine if Infliximab is effective in inhibiting tumor
growth as a result of tumor cell contamination at the site
of surgical wound, the growth characteristics of perito-
neal tumor was also studied. In the resected model peri-
toneal tumor was observed in 10 control mice and in 6
animals treated with Infliximab. Whereas at day 10 there
was still some ambiguity about the presence of peritoneal
tumors, at days 17 and 21 the spatial growth of this
tumor in these mice were distinct from the primary
recurrent tumor and allowed for accurate ultrasound
quantification. As in the case with the resected tumor,
high resolution sonography based quantification of peri-
toneal tumor volume revealed a different temporal
growth pattern between controls and Infliximab treated
groups between days 17 and 21 (Figure 4 and MANOVA
repeated measurements F-test for interaction of time and
group: days 10, 17, and 21: p = 0.06; days 17 and 21 p =
0.02). This was reflected by the difference in volume at
day 21 between the two groups which showed a trend
(156.6 ± 83.6 mm
3 for infliximab compared to 310.0 ±
49.8 mm
3 for the control group, p = 0.11).
A comparison of the temporal response patterns of
the two groups revealed a significantly slower tumor
growth rate for the Infliximab group from day 17 to day
21. The mean increase in peritoneal tumor volume was
A. B.
Figure 3 Sonographic volume measurement and end-point tumor weight of the recurrent tumor in the resected model. (A)
Sonographic volume measurement and end-point tumor weight of the recurrent tumor in the resected model. Significance of group differences
at each day was determined by 2-tailed student t-test (*: p < 0.05, n = 20). Measurements were performed on the respective day indicated
following tumor cell inoculation. (B). Group differences for volume measurements by sonography, both longitudinally measured changes
between day 7 and 21 and cross-sectional final volumes at day 21, compared to group differences by physical determination of tumor weight
(post mortem), n = 16. Box shows 25 - 75 percentile, whiskers 10 - 90 percentiles, + indicates mean and line the median. Significance was
determined by 2-tailed Student t-test (*: p < 0.05,: p < 0.1).
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3/day in the group on Infliximab treat-
ment compared to 54.4 ± 9.4 mm
3/day for the controls
(n = 16, p = 0.02). Therefore, Infliximab is effective in
slowing the rate of peritoneal tumor growth at a time
point when the tumor is established and larger.
Discussion
If the survival rate for patients with pancreatic cancer is
to improve, new agents which target specific cellular
pathways and their effect in combination with other
drugs needs to be explored. We have previously reported
o nt h ee s t a b l i s h m e n to far e s e c t a b l em o u s em o d e lf o r
pancreatic cancer for preclinical testing of adjuvant and
neoadjuvant drug efficacy [3-5]. In this study we have uti-
lized this mouse model to report on the non-invasive
detection of pancreatic tumor growth in response to the
TNF-alpha inhibitor Infliximab. Tumor progression was
evaluated using a 3D high resolution sonography. We
report here that longitudinal sonography measurement of
tumor volume in vivo confirmed the inhibitory effect of
Infliximab on primary tumor growth in both the resected
and the non-resected models. End point differences in
volume measured by sonography showed agreement with
differences in tumor weight between the two groups
measured post mortem. The findings indicate that for
both primary and resected tumor models of pancreatic
cancer, longitudinal ultrasound measurements can be
used to reliably monitor therapeutic efficacy in vivo.
Additionally, it permits to study the temporal develop-
ment of tumor growth sequentially in a given animal pro-
viding more detailed insight into the dynamics of tumor
growth and therapeutic effects.
Measurement of the dynamics of tumor growth
revealed that in both models tumor growth continued to
increase with Infliximab treatment but the rate of
increase was less than that of the untreated tumor. For
the primary tumor model reduction in growth rate was
evident following 9 days of Infliximab administration.
The reduction in growth rate was maintained throughout
the duration of the experiment. A significant difference
i nt u m o rv o l u m ew a sf i r s to b s e r v e da tt h ef i n a lt i m e
point on day 21. Therefore in the primary tumor model,
Infliximab treatment was particularly effective in redu-
cing tumor growth rate at the latter stages when the
tumor is well established and palpable. In contrast, in the
resection model, a significant reduction in tumor growth
rate was observed following 7 days of Infliximab treat-
ment (from day 10) which led to reduced tumor volume
already at day 17 which was borderline significant.
Between day 17 and 21, although the slower growth rate
of the Infliximab group was not significant, tumor
volume was still significantly less than the control at day
21. Longitudinal sonography thus allow to detect variable
rates of tumor growth not accessible by post mortem
measurements of tumor volume or weight. The findings
indicate advantages for time dependent monitoring of
tumor growth to study drug action and efficacy.
Local tumor cell dissemination associated with tumor
resection and the inflammatory microenvironment fol-
lowing resection contributes to disseminated tumor cell
proliferation and metastases. Sonography measurements
in the resection model revealed a significant reduction
i nt h eg r o w t hr a t eo fp e r i t o n e a lt u m o r sf r o md a y1 7
with a trend for smaller tumor volume in the Infliximab
treated group at day 21. The findings suggest that Inflix-
i m a bw o u l db ee f f e c t i v ea sap o s t o p e r a t i v et r e a t m e n t
strategy for control of inflammatory reactions.
Conclusion
In this study we have performed in vivo imaging to longi-
tudinally monitor the growth rate of tumors in response
to Infliximab which targets the TNF-alpha signalling path-
way. In the setting of primary tumor growth and recurrent
tumor growth we identify therapeutic efficacy of Inflixi-
mab to be associated with a 45 - 78% decrease in the
growth rate of the tumor. We postulate that in such clini-
cal settings, an agent will have therapeutic efficacy if it is
able to stabilize the tumor growth rate. Although the fail-
ure to eradicate a tumor will not result in a cure, a cytore-
duced tumor may nevertheless improve clinical outcome
by not growing to a point where it becomes a deadly dis-
ease. In the resected model, Infliximab may be particularly
effective at the early stages of tumor recurrence. We also
show that Infliximab is also therapeutically efficacious
against tumor growth in the postoperative surgical field.
Finally we demonstrate that high resolution sonography is
Figure 4 Sonographic measurement of the volume of the
peritoneal carcinomatosis in the resected model. Significance of
group differences at each day was determined by 2-tailed student t-
test (: p < 0.12). Measurements were performed on the respective
day indicated following tumor cell inoculation.
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tumor growth.
The inhibition of signaling pathways as a therapeutic
approach either by a single agent or in combination with
chemotherapeutic agents can result in improved efficacy.
In particular establishment of those time window during
which different molecularly targeted agents are effica-
cious can lead to a novel paradigm of temporal targeting
in cancer treatment. As more targeted therapies enter
into clinical trials new models of proliferation and growth
kinetics need to be established in order to obtain the true
clinical potential of the drug. This can only be studied in
vivo in longitudinal treatment studies employing molecu-
lar imaging or micro morphometric imaging approaches
such as those investigated in this study. The establish-
ment of reliable evaluation of anti-tumor efficacy in ani-
mal models is a prerequisite for improved success rate of
emerging therapeutics in clinical trials.
Additional material
Additional file 1: powerpoint, Immunohistochemical detection of
cytokeratin using the pan-cytokeratin antibody KL-1 (AbCAM) on
cryosections. Figure containing immunohistochemical staining.
Immunohistochemical detection of cytokeratin using the pan-cytokeratin
antibody KL-1 (AbCAM) on cryosections. Immunohistochemical analysis
was performed using the streptavidin-peroxidase technique and DAKO
EnVision Systems (Dako Cytomation GmbH, Hamburg, Germany)
according to the manufacturer’s protocol. (Panel A) Four representative
primary control tumors (untreated) depict a dense tumor parenchyma
consisting of human tumor cells. (Panel B) Four representative Infliximab
treated primary tumor showing less dense parenchyma but increased
stromal density.
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